Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q2 2024 · 10-Q
Revenue$326.00K$326.00K−17.9% vs Q2 2023 Net Income-$1.00M-$1.00MN/M vs Q2 2023 EPS Diluted-$0.01-$0.01N/M vs Q2 2023 Gross Profit$177,000−10.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flowderived-$883,000N/M Margins · derivedGross margin54.3%+4.7 pt vs Q2 2023
Operating margin-295.7%−29.2 pt vs Q2 2023
Net margin-307.4%−40.4 pt vs Q2 2023
ended Jan 31, 2024 · filed Mar 18, 2024 · 47 d after period end